Bristol-Myers Squibb

LSP, BMS team on European life sciences

Tuesday, November 24, 2015

Specialist healthcare investment firm LSP, also known as Life Sciences Partners, has formed a strategic collaboration with Bristol-Myers Squibb (BMS) in which the companies will work together to identify European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.

[Read More]

Bristol-Myers Squibb to acquire Cardioxyl

Monday, November 2, 2015

Bristol-Myers Squibb will acquire all of the issued and outstanding capital stock of Chapel Hill, N.C.-based Cardioxyl Pharmaceuticals, a private biotechnology company focused on cardiovascular disease. The acquisition will give Bristol-Myers Squibb full rights to Cardioxyl’s lead asset CXL-1427, a novel nitroxyl (HNO) donor (prodrug) in phase II clinical development as an intravenous treatment for acute decompensated heart failure (ADHF).

[Read More]

Bristol-Myers Squibb, Five Prime collaborate

Thursday, October 15, 2015

Bristol-Myers Squibb and Five Prime Therapeutics have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008, which is in phase I development for immunology and oncology indications. The agreement replaces the companies’ existing clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s programmed-death 1 (PD-1) immune checkpoint inhibitor, with FPA008 in six tumor types.

[Read More]

FDA approves cancer drug Keytruda

Monday, October 5, 2015

The FDA has granted Accelerated Approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

[Read More]

EMD Serono appoints U.S. CMO

Wednesday, September 30, 2015

EMD Serono, the U.S. biopharmaceutical business of Germany-based Merck, has appointed Joseph Leveque, M.D., as U.S. chief medical officer. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive the execution of crucial medical initiatives.

[Read More]

Albireo appoints Cooper as CEO

Thursday, September 24, 2015

Ron Cooper has joined Albireo, a privately held company focused through its operating subsidiary on the development of bile acid modulators to treat orphan pediatric and adult liver diseases, NASH and gastrointestinal disorders, as president and chief executive officer.

[Read More]

Report: Cancer deaths hitting U.K. in wallet

Tuesday, September 15, 2015

A new report says the difference in cancer survival rates between England and rest of Europe has stood at about 10% for the past 20 years, and closing that divide would add about £117 million ($180 million) a year to the U.K. economy.

[Read More]

PPD adds Michael Gold to neuroscience team

Thursday, September 10, 2015

Pharmaceutical Product Development (PPD) has announced that Michael Gold, M.D., has joined PPD’s neuroscience team to serve as vice president of global product development, strengthening the company’s ability to help biopharmaceutical clients manage the complex world of nervous system disorders and deliver therapies more efficiently and cost-effectively.

[Read More]